Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation

Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation

Abstract Background Non-melanoma skin cancers (NMSC) are the most common malignancies worldwide. While early-stage lesions can be definitively treated with local therapies, advanced stage cutaneous squamous cell carcinoma (cSCC) often requires systemic treatments such as PD-1 inhibitors. These treat...

Full description

Saved in:
Bibliographic Details
Main Authors: Itamar Averbuch, Nofar Edri, Nethanel Asher, Gal Markel, Daniel Hendler, Hadas Ditzian Kugler, Eyal Yosefof, Noga Kurman
Format: Article
Language:English
Published: Springer 2025-07-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Cutaneous squamous cell carcinoma
PD-1 inhibitors
Anti-PD-1 therapy discontinuation
Online Access:https://doi.org/10.1007/s00262-025-04115-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04115-y

Similar Items